United States, 02 January 2026 – The FDA has issued a Request for Information (RFI) for a new contracting vehicle designed to allow Venture Capital (VC) firms to act as prime contractors. This “FIRE” initiative aims to sideline intermediaries, allowing innovative portfolio companies to secure government work faster and with less red tape.
The U.S. Food and Drug Administration (FDA) has announced the Foundational Innovation and RAPID Engagement (FIRE) initiative, a proposed contracting model seeking to modernize how the agency accesses breakthrough technology. By establishing direct contracts with Venture Capital firms, the FDA aims to bypass traditional “middlemen” and allow startups in AI, biotechnology, and medical devices to work directly with the agency as subcontractors.
KEY UPDATES IN FDA CONTRACTING APPROACH
The RFI (Request # FDA-26-132067) outlines a shift away from labor-based contracts toward scalable technology solutions. Key components include:
- VC as Prime Contractor: The FDA proposes signing contracts directly with qualified VC firms, who will handle the administrative burden of government contracting.
- Portfolio Companies as Subcontractors: Any company within an approved VC’s portfolio can compete for task orders without needing to be a prime contractor themselves.
- Focus on Scalability: The model prioritizes “research, technology deployment, and regulatory innovation” over the traditional staffing-heavy models used by large systems integrators.
This approach addresses the “longstanding challenges” small firms face when navigating federal bureaucracy, which Commissioner Marty Makary noted has “limited engagement with innovative companies”.
IMPACT ON MEDTECH SECTOR
This potential shift offers significant advantages for VC-backed medical device manufacturers and digital health startups:
- Faster Market Access: Removes the need for startups to build expensive internal government contracting departments.
- Direct Revenue Streams: Opens a direct pipeline to FDA funding for piloting and deploying new technologies.
- Reduced Barriers: Mitigates the “complex federal bureaucracy” that currently disincentivizes top talent from working with the government.
HOW COMPANIES CAN PARTICIPATE
The FDA is currently seeking feedback on the feasibility of this model. To participate:
- Review the RFI: Analyze the “FIRE” proposal (FDA-26-132067) to understand the structural requirements.
- Engage Investors: VC firms are the primary respondents; manufacturers should urge their investors to respond to the RFI.
- Submit Feedback: Responses are due by January 18, 2026, at 2:00 PM EST.
External links: